Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.
about
Role of calcium in polycystic kidney disease: From signaling to pathologyA polycystin-centric view of cyst formation and disease: the polycystins revisitedPolycystic liver diseases: advanced insights into the molecular mechanismsImproved Structure and Function in Autosomal Recessive Polycystic Rat Kidneys with Renal Tubular Cell TherapyEffect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK RatsPharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.Mutation of Plekha7 attenuates salt-sensitive hypertension in the rat.Cyst formation following disruption of intracellular calcium signalingImpaired epithelial Na+ channel activity contributes to cystogenesis and development of autosomal recessive polycystic kidney disease in PCK rats.Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 modelEffects of hydration in rats and mice with polycystic kidney disease.Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trialThe effects of mycoplasma contamination upon the ability to form bioengineered 3D kidney cysts.Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease.Vasopressin and disruption of calcium signalling in polycystic kidney disease.The Future of Polycystic Kidney Disease Research--As Seen By the 12 Kaplan Awardees.The Polycystin-1, Lipoxygenase, and α-Toxin Domain Regulates Polycystin-1 Trafficking.Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease.Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease.Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 SubfamiliesA cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease.Pharmacological management of polycystic kidney disease.An approach to cystic kidney diseases: the clinician's view.Novel therapeutic approaches to autosomal dominant polycystic kidney disease.Vasopressin receptor antagonists.Therapeutic Targets in Polycystic Liver Disease.Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease.Role of apoptosis in the development of autosomal dominant polycystic kidney disease (ADPKD).Sclt1 deficiency causes cystic kidney by activating ERK and STAT3 signaling.B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis.Genetic Mechanisms of ADPKD.New Insights into the Molecular Mechanisms Targeting Tubular Channels/Transporters in PKD Development.Polycystin and calcium signaling in cell death and survival.The zebrafish Kupffer's vesicle as a model system for the molecular mechanisms by which the lack of Polycystin-2 leads to stimulation of CFTR.TGR5 in the Cholangiociliopathies.Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 TrialGeneration and phenotypic characterization of Pde1a mutant mice.
P2860
Q26770740-B8873DF1-EC77-40FC-B70E-48F071714148Q26800974-02C87CF2-6E21-4F6A-BE0D-E2933DFD924EQ27001174-12BA3804-85AF-4D3C-A43A-2FA5D52A458CQ27303409-DB7A2B9F-9941-446C-B493-BFA29F37BD38Q30412552-CBF03268-CD3B-42F4-8D14-E4100C0B41EAQ33824148-9590DA47-253C-4777-9B66-3F1CCD8497C3Q33872509-0D69763E-8B26-446F-9AA1-725C1E49A3D9Q34144270-D1967799-D9B9-4EE7-8154-966DD3EFE5D9Q34314347-16F6F9DC-4288-4739-9939-9B4B2160500BQ34714611-BEFD8DDD-8E67-4796-8D66-BE4443AB1C37Q34787786-C4722CF9-2232-43A9-97D3-1FC5B665E911Q35035244-F3A2B9DE-F725-4245-8744-7277B4274FB5Q35163905-36119E3A-436E-4153-929A-3D82FD5FE5B7Q35582371-962B1BB8-4EA0-479D-954C-AC890628CECCQ35890367-1F17071B-B057-44FC-B007-FC612F850D96Q35962991-C20EB006-DCD4-49D2-989D-6EF23FAB3666Q36003176-DEC3A17F-E8DC-45B3-A247-3C1F90BC4A72Q36746031-37B63949-0775-4DD5-B0DD-74EB07DACB73Q36746073-6AD6FF5A-61E7-4680-AEBD-9C564A75B573Q36753925-D48A0541-A045-445E-BBD4-D0650B681981Q36849194-BA818440-544E-43B5-8A51-C30499E760F6Q37529873-AB4D3F80-F363-401D-BDDA-7ABCB9C7501FQ38199755-35E91E03-A968-4749-B6EA-2355F329D54EQ38255292-BAF76415-0099-4DC4-8806-E487F42F6CB5Q38273327-D520E419-B99D-49E9-8D20-D3029B838E35Q38325590-F89256B5-542A-4CE9-B50E-69F3DBA82F56Q38443908-C89D7471-5ADB-4E7D-9E63-CB941BBAD355Q38668934-3B828F0E-87FD-49DE-B326-1FBCE7B2D792Q38754935-B57F8D52-503F-4E66-8258-0B502C44DDC7Q38795694-6FEC8484-69ED-42EA-882B-E9370A59D328Q38833791-604CE6BA-1850-497B-B14C-ECAF6102DBB2Q38853071-5BC72FB2-62F1-47EC-9A67-20B2BE279BB1Q38868452-95AE4355-80AE-4F12-B1AA-3272DCFB7970Q38978453-8251CEE2-E18D-41B9-96A3-B203FDDF5AA5Q39030255-9C01A13E-A884-43A0-97CE-C2BAE21B3853Q39364250-193C8ED3-543E-49FC-9EDC-91D954F21CC2Q40471569-FC77AE0F-2D78-4655-9CEB-749DE2EA9203Q40867711-02E10289-6B9F-413B-9264-DDCC53DE7051Q41076909-F66C65B8-73D9-4FBC-A229-289CF6178D33Q41153428-495B820D-60F2-475A-B2E5-C98A5EFF5E6D
P2860
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.
@en
type
label
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.
@en
prefLabel
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.
@en
P2860
P356
P1476
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.
@en
P2093
Peter C Harris
Vicente E Torres
P2860
P356
10.1681/ASN.2013040398
P577
2013-12-12T00:00:00Z
2014-01-01T00:00:00Z